Records outcomes of laser treatment for prostate cancer through the body's outer skin
Collects past records of men treated with transperineal laser ablation for prostate cancer.
Key facts
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Oct 2021
- Expected to end
- 1 Oct 2027
- Type of study
- Observational
- Treatments tested
- Transperineal Laser Ablation of Prostate Cancer
- Record updated
- 20 December 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men who were treated with transperineal laser ablation (TPLA) for localized prostate cancer. Data on their treatment is collected in a registry.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Localized prostate cancer, confirmed by tissue examination
- Earlier treatment
- Must have been treated with TPLA for prostate cancer
Main reasons for not taking part
- Under 18 years of age
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed
Who cannot take part
- Age < 18 years
Where in Netherlands
- Amsterdam University Medical CentersAmsterdam, NetherlandsContact: L. A. van Riel, MDTaking people
About the trial
What the trial wants to find out
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes.
Read full original descriptionShow less
Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort.
Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa.
Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.
Treatments tested
- Transperineal Laser Ablation of Prostate Cancer
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Transperineal Laser Ablation Treatment for Prostate Cancer Registry: a Retrospective and Multicenter Evaluation
- Plain-language title
- Records outcomes of laser treatment for prostate cancer through the body's outer skinGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 20 December 2021